

**Supplemental Figure 1. Cellular viability in the presence of BAY.** Bone marrow-derived M𝚽 were treated with 1.0 µM BAY for 30 min prior to infection with *O. tsutsugamushi* (10 MOI). Viability was assessed at 6 hpi via live-dead staining. One-way ANOVA with Dunnett’s multiple comparison test was performed across all treatment groups, using mock controls as the reference. \*\*, *p* < 0.01; \*\*\*, *p* < 0.0001; \*\*\*\*, *p* < 0.0001.

****

**Supplemental Figure 2. PIC and R406 exhibit different capacities to abrogate type 1 responses during infection.** Bone marrow-derived M𝚽 were treated with Syk-inhibitors for 30 min prior to infection with *O. tsutsugamushi* (10 MOI). (A) Effect of PIC (5, 25, and 50 µM, respectively) on target genes at 6 hr post-infection. (B)Effect of R406 (0.5, 2.5, 5.0 µM) on target genes at 6 hr post-infection. qRT-PCR analyses of target genes relative to GAPDH are shown as mean ± SEM. One-way ANOVA with Dunnett’s multiple comparison test was performed across all treatment groups. For groups in comparison to mock controls: \*\*\*\*, *p* < 0.0001. For infected-and-treated groups in comparison to infected-but-untreated samples: ####, *p* < 0.0001.

|  |  |  |
| --- | --- | --- |
| Gene Target | Forward 5’-3’ | Reverse 5’-3’ |
| *Clec4e* (Mincle) | AGTGCTCTCCTGGACGATAG | CCTGATGCCTCACTGTAGCAG |
| *Clec5a* (MDL-1) | TCGGGGCTTATCGTAGTAGTG | TGTAGGCATGGTACTTTCGTCAT |
| *Clec6a* (Dectin1) | AAGCGGAGCAGAATTTCATCA | CCATTTGCCATTACCTTGTGGA |
| *Clec12a* | AGAAGTCTGACAAATGTGGGGG | CCAATGAACAGCAGAAGGCATA |
| *Il12p40* | GGAAGCACGGCAGCAGAATAA | CTTGAGGGAGAAGTAGGAATG |
| *Il27p28* | CTGTTGCTGCTACCCTTGCTT | CACTCCTGGCAATCGAGATTC |
| *MerTK* | CAGGGCCTTTACCAGGGAGA | TGTGTGCTGGATGTGATCTTC |
| *Mx1* | GACCATAGGGGTCTTGACCAA | AGACTTGCTCTTTCTGAAAAGCC |
| *Oas1b* | GGGCCTCTAAAGGGGTCAAG | TCAAACTTCACTCCACAACGTC |
| *Oas2* | TTGAAGAGGAATACATGCGGAAG | GGGTCTGCATTACTGGCACTT |
| *Oas3* | TCTGGGGTCGCTAAACATCAC | GATGACGAGTTCGACATCGGT |
| *Tnf* | CCCTCACACTCAGATCATCTTCT | GCTACGACGTGGGCTACAG |
| GAPDH | TGGAAAGCTGTGGCGTGAT | TGCTTCACCACCTTCTTGAT |

**Supplemental Table 1.** Primers for qRT-PCR analysis